Fig. 5

Biodistribution of Neu-LPs in vitro and in vivo. A Schematic illustration of the in vitro transmembrane model to evaluate the penetration and transport of Neu-LPs across a monolayer of HUVECs. B Quantification of Neu-LP distribution in the transwell system (n = 3). C, D Ex vivo fluorescence images (C) and quantification (D) of hearts from MI/R mice after treatment with Neu-LPs, LPs, or PBS at various timepoints (3 h, 1 day, and 3 days) (n = 6). *P < 0.05 and ***P < 0.001 compared with the PBS group. E Fluorescence microscopy images of Neu-LP distribution in infarcted areas. Scale bars, 100 μm. F Quantitative analysis of the fluorescence intensity of Neu-LPs (n = 6). ***P < 0.001 compared with the LPs group. G, H Representative fluorescence images (G) and quantitative analysis of fluorescence intensity (H) in major organs after intravenous injection of Neu-LPs (n = 6). *P < 0.05 and **P < 0.01 compared with the PBS group. Comparisons between two groups were performed with Student’s t-test. One-way analysis of variance (ANOVA) was employed for comparisons among more than two groups. Data are presented as mean ± SD